Literature DB >> 11181553

Cloning and in vitro characterization of alpha 1(I)-collagen 11 beta-hydroxysteroid dehydrogenase type 2 transgenes as models for osteoblast-selective inactivation of natural glucocorticoids.

H Woitge1, J Harrison, A Ivkosic, Z Krozowski, B Kream.   

Abstract

The NAD-dependent enzyme, 11beta-hydroxysteroid dehydrogenase type II (11 beta HSD2), catalyzes the unidirectional conversion of biologically active glucocorticoids to inactive metabolites. In vivo, 11 beta HSD2 protects the mineralocorticoid receptor from activation by glucocorticoids in mineralocorticoid target tissues such as kidney. The goal of the present study was to use targeted overexpression of 11 beta HSD2 as a novel means of disrupting glucocorticoid signaling in osteoblastic cells. Rat 11 beta HSD2 complementary DNA was cloned downstream of a 2.3- and 3.6-kb alpha 1(I)-collagen (Col1a1) promoter fragment to produce the expression plasmids Col2.3-HSD2 and Col3.6-HSD2, respectively, which were transiently and/or stably transfected in osteoblastic ROS 17/2.8 and MC3T3-E1 cells. Transgene messenger RNA and protein were detected in transfected cells by Northern blot analysis and immunostaining, respectively. Transfection of 11 beta HSD2 led to higher rates of conversion of [(3)H]corticosterone to [(3)H]dehydrocorticosterone and reduced glucocorticoid-dependent regulation of a mouse mammary tumor virus promoter-reporter construct, cell growth, and messenger RNA markers compared with transfection of a control vector. Expression of 11 beta HSD2 under the control of Col1a1 promoter fragments may provide a novel model to study the role of glucocorticoid signaling in osteoblastic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181553     DOI: 10.1210/endo.142.3.8044

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Genetic approaches to determine the role of glucocorticoid signaling in osteoblasts.

Authors:  John R Harrison; Henning W Woitge; Barbara E Kream
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

Review 2.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

3.  Role of glucocorticoid-induced leucine zipper (GILZ) in bone acquisition.

Authors:  Guodong Pan; Jay Cao; Nianlan Yang; Kehong Ding; Cheng Fan; Wen-Cheng Xiong; Mark Hamrick; Carlos M Isales; Xing-Ming Shi
Journal:  J Biol Chem       Date:  2014-05-23       Impact factor: 5.157

4.  Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.

Authors:  Maobin Yang; Lorin B Trettel; Douglas J Adams; John R Harrison; Ernesto Canalis; Barbara E Kream
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

5.  Calcitonin induces expression of the inducible cAMP early repressor in osteoclasts.

Authors:  Maobin Yang; Barbara E Kream
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

6.  11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy.

Authors:  C G Fenton; C L Doig; S Fareed; A Naylor; A P Morrell; O Addison; C Wehmeyer; C D Buckley; M S Cooper; G G Lavery; K Raza; R S Hardy
Journal:  Arthritis Res Ther       Date:  2019-08-16       Impact factor: 5.156

7.  Coordinated transcriptional regulation of bone homeostasis by Ebf1 and Zfp521 in both mesenchymal and hematopoietic lineages.

Authors:  Riku Kiviranta; Kei Yamana; Hiroaki Saito; Daniel K Ho; Julius Laine; Kati Tarkkonen; Vappu Nieminen-Pihala; Eric Hesse; Diego Correa; Jorma Määttä; Lino Tessarollo; Evan D Rosen; William C Horne; Nancy A Jenkins; Neal G Copeland; Soren Warming; Roland Baron
Journal:  J Exp Med       Date:  2013-04-08       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.